ArticleAJOG global reports2026
Omicron SARS-CoV-2 maternal infection is associated with favorable fetomaternal outcomes and fewer placental vascular malperfusion lesions compared with previous variants.
Article in AJOG global reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe SARS-CoV-2 pandemic, declared in March 2020, has affected over 570 million people worldwide. The impact on pregnant women and fetuses remains unclear, particularly with the Omicron variant, which appears to increase the infection rates.
objectiveThis retrospective study describes fetal-maternal complications and placental features in Omicron-variant SARS-CoV-2 infections during pregnancy and compares them with those associated with other variants and with noninfected controls from published studies examining the association between SARS-CoV-2 infection and placental pathology. STUDY
designWe analyzed all consecutive placentas referred to our hospital from May 2021 to March 2023, associated with proven Omicron-variant SARS-CoV-2 maternal infection during pregnancy.
resultsAmong the 315 placentas studied, fetal-maternal complication rates were comparable with those in the general population, including preeclampsia (0.6%), intrauterine growth restriction (5%), small for gestational age (9.1%), and preterm delivery (3.1%). We observed a significantly lower rate of hypotrophic placentas below the 10th percentile (4.1% vs 15.0% [
conclusionThis large Omicron-variant placentas cohort highlighted clinically, an overall good outcome, and histologically significantly less vascular malperfusion and chronic deciduitis than in non-Omicron SARS-CoV-2 variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.